What is KIORA PHARMACEUTICALS INC's earnings per share (EPS)?

KIORA PHARMACEUTICALS INC (KPRX) reported diluted earnings per share of -$2.64 for fiscal year 2025. This represents a -403.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

KIORA PHARMACEUTICALS INC Financials

KPRX

FY2025 annual

Revenue $0 -100.0% YoY

Net Income -$11K -401.4% YoY

EPS (Diluted) -$2.64 -403.4% YoY

Free Cash Flow -$10.1M -217.8% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 7, 2026 Currency USD FYE December

KIORA PHARMACEUTICALS INC (KPRX) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI KPRX FY2025 2026-08-30

A single reported commercial year pairs operating profitability with unusually strong cash conversion and a liquid, lightly leveraged balance sheet

In FY2024, free cash flow of $8.6M exceeded operating income of $4.5M, while free-cash-flow margin reached 53.4% against an operating margin of 28.2%; the gap suggests cash generation benefited from balance-sheet movements or other non-operating factors, not just reported earnings. Because only one annual row passes the revenue validity check, this is a snapshot rather than a proven trend.

Liquidity and leverage point in the same direction: a 4.9x current ratio and 0.4x debt-to-equity ratio indicate substantial short-term asset coverage alongside limited balance-sheet leverage in FY2024.

The business also committed $22.7M to investing activities while reporting only $6.3K of capital expenditures, indicating that the year's investment cash use was driven by something other than ordinary property-and-equipment spending. Reported liquidity equaled 20.6 months of the latest annual operating outflow, but this comparison should not be treated as a forecast.

Some figures from recent filings were inconsistent and were omitted from this summary.

Financial Health Signals

Financial health score not available

KIORA PHARMACEUTICALS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-8.93

KIORA PHARMACEUTICALS INC scores -8.93, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($11.1M) relative to total liabilities ($8.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

KIORA PHARMACEUTICALS INC passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

KIORA PHARMACEUTICALS INC reported a net loss of $11K while operations used $10.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

KIORA PHARMACEUTICALS INC reported an operating loss of $12.8M against $20K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

YoY-100.0%

KIORA PHARMACEUTICALS INC generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

EBITDA

-$12.8M

YoY-382.7%

KIORA PHARMACEUTICALS INC's EBITDA was -$12.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 382.7% from the prior year.

Net Income

-$11K

YoY-401.4%

KIORA PHARMACEUTICALS INC reported -$11K in net income in fiscal year 2025. This represents a decrease of 401.4% from the prior year.

EPS (Diluted)

-$2.64

YoY-403.4%

KIORA PHARMACEUTICALS INC earned -$2.64 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 403.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$10.1M

YoY-217.8%

KIORA PHARMACEUTICALS INC recorded an outflow of $10.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 217.8% from the prior year.

Cash & Debt

$8.7M

YoY+129.3%

5Y CAGR+49.0%

10Y CAGR+0.4%

KIORA PHARMACEUTICALS INC held $8.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

YoY+31.7%

KIORA PHARMACEUTICALS INC had 4M shares outstanding in fiscal year 2025. This represents an increase of 31.7% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-0.1%

YoY-0.1pp

5Y CAGR+70.5pp

KIORA PHARMACEUTICALS INC's ROE was -0.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.1 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$10.8M

YoY+37.5%

5Y CAGR+24.8%

10Y CAGR+14.8%

KIORA PHARMACEUTICALS INC invested $10.8M in research and development in fiscal year 2025. This represents an increase of 37.5% from the prior year.

Capital Expenditures

$111K

YoY+1670.9%

5Y CAGR+40.7%

KIORA PHARMACEUTICALS INC invested $111K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 1670.9% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

KPRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

KPRX quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Revenue	N/A	$0-100.0%	$16.0M	$0	N/A	$0-100.0%	$12K-99.6%	$2.7M+62.5%	$1.7M+305.5%	$408K-39.1%	$669K	$0	N/A
R&D Expenses	N/A	$10.8M+37.5%	$7.8M+94.7%	$4.0M+16.8%	$3.4M-35.5%	$5.4M+50.0%	$3.6M-33.8%	$5.4M-33.1%	$8.1M-22.0%	$10.3M+22.7%	$8.4M+210.0%	$2.7M+411.6%	$531K
SG&A Expenses	N/A	$5.7M+3.7%	$5.5M+18.9%	$4.7M-43.7%	$8.3M+55.5%	$5.3M+14.3%	$4.7M+5.7%	$4.4M-0.8%	$4.4M-4.2%	$4.6M-17.1%	$5.6M+41.2%	$4.0M+105.1%	$1.9M
Operating Income	N/A	-$12.8M-384.5%	$4.5M+135.8%	-$12.6M-2.3%	-$12.3M+13.5%	-$14.2M-107.3%	-$6.9M	N/A	-$10.8M	N/A	N/A	N/A	N/A
Interest Expense	N/A	$20K-6.9%	$21K+92.7%	$11K+29.5%	$9K+25.5%	$7K+63.7%	$4K+1188.0%	$325-68.8%	$1K-14.4%	$1K+341.8%	$275-100.0%	$1.9M+337.9%	$442K
Income Tax	N/A	-$1.3M-162.1%	$2.1M+2186.3%	$90K+179.9%	-$113K+41.3%	-$193K-1697.7%	$12K-87.4%	$95K+10.9%	$86K+106.4%	-$1.3M	$0	N/A	N/A
Net Income	N/A	-$11K-401.4%	$4K+128.7%	-$13K+99.9%	-$13.6M+1.4%	-$13.8M-100.7%	-$6.9M+3.3%	-$7.1M+34.4%	-$10.8M+18.2%	-$13.2M+0.9%	-$13.3M-59.1%	-$8.4M-440.6%	-$1.6M
EPS (Diluted)	-$2.51	-$2.64-403.4%	$0.87	-$0.02	-$18.55	-$57.12	-$1.49	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	$0	$0	$0	N/A	$0
R&D Expenses	$2.1M-2.2%	$2.1M	N/A	$2.7M+5.4%	$2.6M+2.3%	$2.5M	N/A	$2.2M
SG&A Expenses	$1.4M-14.2%	$1.6M	N/A	$1.4M+6.6%	$1.4M-9.1%	$1.5M	N/A	$1.4M
Operating Income	-$2.2M+11.8%	-$2.5M	N/A	-$794K+66.8%	-$2.4M-2.8%	-$2.3M	N/A	-$3.6M
Income Tax	$0	$0	N/A	-$643K-473.9%	-$112K-191.1%	$123K	N/A	$0
Net Income	-$2.1M+14.0%	-$2.4M	N/A	$27K+101.2%	-$2.2M+1.8%	-$2.2M	N/A	-$3.4M
EPS (Diluted)	-$0.34+41.4%	-$0.58+63.7%	-$1.60-16100.0%	$0.01+101.9%	-$0.54-3.8%	-$0.52+50.0%	-$1.04-28.4%	-$0.81

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

KPRX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

KPRX quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Total Assets	$24.3M-33.5%	$36.5M+166.1%	$13.7M-26.6%	$18.7M-7.2%	$20.1M+31.5%	$15.3M+51.3%	$10.1M-29.2%	$14.3M-0.2%	$14.3M+47.0%	$9.7M+2.3%	$9.5M+576.0%	$1.4M
Current Assets	$21.7M-26.8%	$29.7M+527.0%	$4.7M-38.3%	$7.7M-14.6%	$9.0M+420.8%	$1.7M-60.1%	$4.3M-49.0%	$8.5M+0.2%	$8.5M+103.6%	$4.2M-56.0%	$9.4M+4219.0%	$219K
Cash & Equivalents	$8.7M+129.3%	$3.8M+54.5%	$2.5M-58.8%	$6.0M-24.1%	$7.9M+562.5%	$1.2M-68.6%	$3.8M-52.8%	$8.0M+2.5%	$7.8M+114.7%	$3.6M-56.7%	$8.4M+4926.4%	$167K
Accounts Receivable	$1.5M+153.3%	$601K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$0	$0-100.0%	$3.6M+138.0%	$1.5M0.0%	$1.5M0.0%	$1.5M	N/A	N/A	N/A
Total Liabilities	$8.1M-24.2%	$10.7M+41.1%	$7.6M+4.6%	$7.3M+31.0%	$5.6M-0.4%	$5.6M+59.7%	$3.5M-34.7%	$5.3M-67.1%	$16.2M+61.4%	$10.1M+194.1%	$3.4M-92.9%	$48.2M
Current Liabilities	$3.6M-39.6%	$6.0M+267.7%	$1.6M-50.1%	$3.3M+103.3%	$1.6M-18.9%	$2.0M+40.3%	$1.4M-63.4%	$3.9M-73.9%	$14.8M+103.0%	$7.3M+113.6%	$3.4M-31.9%	$5.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$278K	$0	N/A	N/A	N/A	N/A	N/A
Total Equity	$16.1M-37.4%	$25.8M+321.6%	$6.1M-46.4%	$11.4M-21.8%	$14.6M+49.8%	$9.7M+46.9%	$6.6M-25.9%	$8.9M+563.8%	-$1.9M-484.9%	-$329K-105.4%	$6.1M+113.0%	-$46.8M
Retained Earnings	-$154.2M-7.6%	-$143.4M+2.4%	-$147.0M-9.3%	-$134.5M-11.2%	-$120.9M-12.9%	-$107.1M-6.8%	-$100.2M-7.6%	-$93.2M-1.5%	-$91.8M-16.8%	-$78.6M-20.4%	-$65.3M-14.8%	-$56.9M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$23.8M+12.0%	$21.2M-12.5%	$24.3M-18.8%	$29.9M-6.5%	$31.9M-6.1%	$34.0M-6.8%	$36.5M-5.3%	$38.5M
Current Assets	$21.3M+13.8%	$18.7M-14.1%	$21.7M-4.2%	$22.7M-8.3%	$24.7M-8.7%	$27.1M-8.7%	$29.7M-6.1%	$31.7M
Cash & Equivalents	$7.1M-35.4%	$11.0M+26.0%	$8.7M+57.9%	$5.5M+435.7%	$1.0M-72.7%	$3.8M-0.6%	$3.8M-32.7%	$5.6M
Accounts Receivable	$1.1M-29.3%	$1.5M+1.4%	$1.5M+25.5%	$1.2M-49.8%	$2.4M+80.8%	$1.3M+122.5%	$601K-66.3%	$1.8M
Total Liabilities	$6.9M-5.1%	$7.3M-10.3%	$8.1M+9.0%	$7.5M-24.1%	$9.8M-4.9%	$10.3M-3.8%	$10.7M+26.5%	$8.5M
Current Liabilities	$2.4M-15.3%	$2.8M-22.9%	$3.6M+40.7%	$2.6M-19.0%	$3.2M-39.6%	$5.3M-12.2%	$6.0M+70.3%	$3.5M
Total Equity	$16.9M+21.0%	$13.9M-13.6%	$16.1M-28.0%	$22.4M+1.3%	$22.1M-6.6%	$23.7M-8.0%	$25.8M-14.2%	$30.0M
Retained Earnings	-$158.7M-1.3%	-$156.6M-1.6%	-$154.2M-4.4%	-$147.7M0.0%	-$147.7M-1.5%	-$145.6M-1.5%	-$143.4M-3.0%	-$139.2M

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

KPRX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

KPRX quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Operating Cash Flow	-$8.5M	-$10.0M-216.4%	$8.6M+189.6%	-$9.6M+8.4%	-$10.4M+2.3%	-$10.7M-45.9%	-$7.3M+10.3%	-$8.2M+24.8%	-$10.8M-67.7%	-$6.5M+23.1%	-$8.4M-88.7%	-$4.5M-369.1%	-$951K
Capital Expenditures	$107K	$111K+1670.9%	$6K	$0	$0-100.0%	$64K+218.1%	$20K	$0-100.0%	$20K-45.9%	$37K	$0	N/A	N/A
Free Cash Flow	-$8.6M	-$10.1M-217.8%	$8.6M+189.5%	-$9.6M+8.4%	-$10.4M+2.9%	-$10.7M-46.4%	-$7.3M+10.0%	-$8.2M+24.9%	-$10.9M-67.0%	-$6.5M+22.7%	-$8.4M	N/A	N/A
Investing Cash Flow	$9.6M	$14.4M+163.7%	-$22.7M	$0-100.0%	$6K+104.1%	-$157K+35.8%	-$244K	$0+100.0%	-$270K-629.7%	-$37K-121.2%	$175K	N/A	N/A
Financing Cash Flow	$4.9M	$266K-98.3%	$15.5M+159.8%	$6.0M-30.8%	$8.6M-51.0%	$17.6M+251.8%	$5.0M+27.5%	$3.9M-65.3%	$11.3M+5.9%	$10.7M+205.1%	$3.5M	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$1.9M+40.2%	-$3.2M-45.0%	-$2.2M-71.3%	-$1.3M+66.5%	-$3.8M-40.6%	-$2.7M-20.1%	-$2.3M-344.8%	$920K
Capital Expenditures	$23K+367.4%	$5K-93.6%	$78K+18035.3%	$431-98.7%	$32K	$0-100.0%	-$45K	$0
Free Cash Flow	-$1.9M+39.5%	-$3.2M-40.2%	-$2.3M-77.4%	-$1.3M+66.8%	-$3.8M-41.8%	-$2.7M-17.7%	-$2.3M-349.7%	$920K
Investing Cash Flow	-$6.9M-227.6%	$5.4M+1.0%	$5.3M-6.8%	$5.7M+764.3%	$664K-75.2%	$2.7M+453.7%	$483K+125.1%	-$1.9M
Financing Cash Flow	$4.9M+584284.2%	-$842-384.5%	$296	$0-100.0%	$265K	$0	$0	$0

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

KPRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

KPRX quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14
Operating Margin	N/A	28.1%	N/A	N/A	N/A	-56960.5%	N/A	-656.3%	N/A	N/A	N/A	N/A
Net Margin	N/A	0.0%	N/A	N/A	N/A	-56901.6%	-264.2%	-654.2%	-3243.5%	-1993.8%	N/A	N/A
Return on Equity	-0.1%-0.1pp	0.0%+0.2pp	-0.2%+118.9pp	-119.1%-24.6pp	-94.5%-23.9pp	-70.5%+36.6pp	-107.2%+13.8pp	-121.0%	N/A	N/A	-137.8%	N/A
Return on Assets	0.0%-0.1pp	0.0%+0.1pp	-0.1%+72.6pp	-72.7%-4.3pp	-68.4%-23.6pp	-44.8%+25.3pp	-70.2%+5.5pp	-75.7%+16.7pp	-92.4%+44.7pp	-137.1%-48.9pp	-88.2%+22.1pp	-110.3%
Current Ratio	5.99+1.0x	4.94+2.0x	2.90+0.6x	2.35-3.2x	5.59+4.7x	0.87-2.2x	3.06+0.9x	2.19+1.6x	0.570.0x	0.57-2.2x	2.76+2.7x	0.04
Debt-to-Equity	0.50+0.1x	0.42-0.8x	1.24+0.6x	0.64+0.3x	0.38+0.4x	0.030.0x	0.00-0.6x	0.60	N/A	N/A	0.56	N/A
FCF Margin	N/A	53.4%	N/A	N/A	N/A	-60844.6%	-303.6%	-657.4%	-1596.4%	-1257.1%	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Return on Equity	-12.3%+5.0pp	-17.3%	N/A	0.1%+9.8pp	-9.7%-0.5pp	-9.3%	N/A	-11.4%
Return on Assets	-8.7%+2.6pp	-11.4%	N/A	0.1%+6.8pp	-6.7%-0.3pp	-6.5%	N/A	-8.9%
Current Ratio	8.97+2.3x	6.68+0.7x	5.99-2.8x	8.79+1.0x	7.76+2.6x	5.14+0.2x	4.94-4.0x	8.97
Debt-to-Equity	0.41-0.1x	0.520.0x	0.50+0.2x	0.33-0.1x	0.440.0x	0.440.0x	0.42+0.1x	0.28

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Aprea Therapeutics, Inc. APRE

$10.1M

Genprex Inc GNPX

$3.0M

Processa Pharmaceuticals Inc PCSA

$5.7M

Cyclacel Phar Pr CYCCP

$9.6M

In8Bio, Inc. INAB

$10.8M

Where KIORA PHARMACEUTICALS INC Ranks

Frequently Asked Questions

What is KIORA PHARMACEUTICALS INC's annual revenue?

KIORA PHARMACEUTICALS INC (KPRX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is KIORA PHARMACEUTICALS INC's revenue growing?

KIORA PHARMACEUTICALS INC (KPRX) revenue declined by 100.0% year-over-year, from $16.0M to $0 in fiscal year 2025.

Is KIORA PHARMACEUTICALS INC profitable?

No, KIORA PHARMACEUTICALS INC (KPRX) reported a net income of -$11K in fiscal year 2025.

What is KIORA PHARMACEUTICALS INC's EBITDA?

KIORA PHARMACEUTICALS INC (KPRX) had EBITDA of -$12.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is KIORA PHARMACEUTICALS INC's return on equity (ROE)?

KIORA PHARMACEUTICALS INC (KPRX) has a return on equity of -0.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is KIORA PHARMACEUTICALS INC's free cash flow?

KIORA PHARMACEUTICALS INC (KPRX) recorded an outflow of $10.1M in free cash flow during fiscal year 2025. This represents a -217.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is KIORA PHARMACEUTICALS INC's operating cash flow?

KIORA PHARMACEUTICALS INC (KPRX) recorded an outflow of $10.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are KIORA PHARMACEUTICALS INC's total assets?

KIORA PHARMACEUTICALS INC (KPRX) had $24.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are KIORA PHARMACEUTICALS INC's capital expenditures?

KIORA PHARMACEUTICALS INC (KPRX) invested $111K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does KIORA PHARMACEUTICALS INC spend on research and development?

KIORA PHARMACEUTICALS INC (KPRX) invested $10.8M in research and development during fiscal year 2025.

How many shares does KIORA PHARMACEUTICALS INC have outstanding?

KIORA PHARMACEUTICALS INC (KPRX) had 4M shares outstanding as of fiscal year 2025.

What is KIORA PHARMACEUTICALS INC's current ratio?

KIORA PHARMACEUTICALS INC (KPRX) had a current ratio of 5.99 as of fiscal year 2025, which is generally considered healthy.

What is KIORA PHARMACEUTICALS INC's debt-to-equity ratio?

KIORA PHARMACEUTICALS INC (KPRX) had a debt-to-equity ratio of 0.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is KIORA PHARMACEUTICALS INC's return on assets (ROA)?

KIORA PHARMACEUTICALS INC (KPRX) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does KIORA PHARMACEUTICALS INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, KIORA PHARMACEUTICALS INC (KPRX) held $17.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.0M over that year. Dividing the one by the other, the reported balance equals about 21 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is KIORA PHARMACEUTICALS INC's Altman Z-Score?

KIORA PHARMACEUTICALS INC (KPRX) has an Altman Z-Score of -8.93, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is KIORA PHARMACEUTICALS INC's Piotroski F-Score?

KIORA PHARMACEUTICALS INC (KPRX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are KIORA PHARMACEUTICALS INC's earnings high quality?

KIORA PHARMACEUTICALS INC (KPRX) reported a net loss of $11K while operations used $10.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can KIORA PHARMACEUTICALS INC cover its interest payments?

KIORA PHARMACEUTICALS INC (KPRX) reported an operating loss of $12.8M against $20K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.